Taxotere Hair Loss Lawsuit | Taxotere Lawsuit
Taxotere Hair Loss Lawsuit | Taxotere Side Effects Lawsuit
Taxotere, chemotherapy medication, Taxotere Lawsuits, Taxotere Hair Loss Lawyer, Taxotere Hair Loss Lawsuits,
Taxotere, a chemotherapy medication used to treat breast and other cancers, may cause permanent alopecia. While a number of studies have suggested that Taxotere chemotherapy could result in permanent hair loss, the drug’s label did not mention this possible side effect until December 2015. Taxotere hair loss lawsuits claim that patients were not properly warned of this risk, and were robbed of the chance to choose an alternative chemo treatment that does not cause this distressing side effect.
Alonso Krangle LLP is now investigating Taxotere hair loss lawsuits, and is offering free Taxotere hair loss lawsuit legal consultations to anyone who experienced permanent alopecia following treatment with this chemotherapy agent. To learn more about the Taxotere lawsuit legal options available to you, please contact Alonso Krangle LLP today to schedule your free Taxotere hair loss lawsuit legal review by filling out our online form or calling 1-888-836-3050.
Taxotere and Hair Loss Side Effect
Manufactured by Sanofi-Aventis, Taxotere (docetaxel) has been available in the U.S. since 1996. It is approved to treat:
- Breast cancer
- Non-small cell lung cancer
- Hormone refractory prostate cancer
- Gastric adenocarcinoma
- Squamous cell carcinoma of the head
- Neck cancer
Many patients treated with Taxotere were told that their hair loss would only be temporary. But a number of studies and reports published in recent years suggest this is not the case:
- A 2011 study that appeared in the American Journal of Dermatopathology found that “there is increased evidence that certain chemotherapy regimens can cause dose-dependent permanent alopecia,” including docetaxel for breast cancer.
- In 2012, a study published in the Annals of Oncology involving 20 women concluded that “permanent and severe alopecia is a newly reported complication of the FEC 100-docetaxel breast cancer regimen.”
- Research presented at the 2015 NCRI Cancer Conference suggested that long-term, significant scalp alopecia (lasting for up to 3.5 years following completion of chemotherapy) may affect 10-15% of patients following treatment of early breast cancer with Taxotere.
- According to “A Head of Our Time,” Sanofi-Aventis has acknowledged that 3% of patients administered Taxotere could experience long-term alopecia. This figure could rise to as high as 6.3% when given in combination with the drugs Adriamycin (doxorubicin) and Cyclophosphamide, per research conducted by the Rocky Mountain Cancer Centers in Colorado.
Taxotere Label Modified
Sanofi-Aventis modified Taxotere’s European label in 2005 to warn of the potential for permanent alopecia. A similar warning was included on the Canadian label in 2012. However, mention of permanent hair loss wasn’t added to the U.S. label until December 2015. Taxotere lawsuit plaintiffs claim that Sanofi-Aventis’s alleged failure to provide adequate warnings deprived patients of the opportunity to undergo chemotherapy with other equally-effective medications, such as Taxol, that are less likely to cause permanent baldness.
Learn More about Filing a Taxotere Lawsuit
If you experienced permanent hair loss or baldness following Taxotere chemotherapy, contact Alonso Krangle LLP to learn more about your Taxotere hair loss lawsuit legal options. Obtain a free Taxotere hair loss lawsuit case review by filling out our online form or calling 1-888-836-3050.
Taxotere Hair Loss Lawsuit Information